Neuropsychiatr Dis Treat. 2005 Dec;1(4):329-43.
The history of barbiturates a century after their clinical introduction.
Neuropsychiatric disease and treatment
Francisco López-Muñoz, Ronaldo Ucha-Udabe, Cecilio Alamo
PMID: 18568113
PMCID: PMC2424120
Abstract
The present work offers an analysis of the historical development of the discovery and use of barbiturates in the field of psychiatry and neurology, a century after their clinical introduction. Beginning with the synthesis of malonylurea by von Baeyer in 1864, and up to the decline of barbiturate therapy in the 1960s, it describes the discovery of the sedative properties of barbital, by von Mering and Fischer (1903), the subsequent synthesis of phenobarbital by this same group (1911), and the gradual clinical incorporation of different barbiturates (butobarbital, amobarbital, secobarbital, pentobarbital, thiopental, etc). We describe the role played in therapy by barbiturates throughout their history: their traditional use as sedative and hypnotic agents, their use with schizophrenic patients in so-called "sleep cures" (Klaesi, Cloetta), the discovery of the antiepileptic properties of phenobarbital (Hauptmann) and their use in the treatment of epilepsy, and the introduction of thiobarbiturates in intravenous anesthesia (Lundy, Waters). We also analyze, from the historical perspective, the problems of safety (phenomena of dependence and death by overdose) which, accompanied by the introduction of a range of psychoactive drugs in the 1950s, brought an end to barbiturate use, except in specific applications, such as the induction of anesthesia and the treatment of certain types of epileptic crisis.
Keywords: anesthesia; barbiturates; epilepsy; history of medicine; sedative-hypnotic drugs; “sleep cures”
References
- Prog Neuropsychopharmacol Biol Psychiatry. 2001 May;25(4):709-27 - PubMed
- Br Med J. 1977 Apr 30;1(6069):1128-30 - PubMed
- Proc Soc Exp Biol Med. 1956 Dec;93(3):544-6 - PubMed
- Neuropsychopharmacology. 1993 Jun;8(4):291-303 - PubMed
- J R Coll Physicians Lond. 1976 Jan;10(2):205-8 - PubMed
- J Neurosurg. 1988 Jul;69(1):15-23 - PubMed
- Hist Psychiatry. 1993 Mar;4(13):83-93 - PubMed
- Am J Psychiatry. 1994 Jun;151(6 Suppl):220-30 - PubMed
- Anaesthesia. 1982 Jul;37(7):726-34 - PubMed
- Mol Chem Neuropathol. 1992 Aug;17(1):21-30 - PubMed
- Lancet. 1952 Apr 12;1(6711):742-4 - PubMed
- Acta Neurol Scand. 1967;43(3):348-56 - PubMed
- Neurology. 2000;54(11 Suppl 4):S30-8 - PubMed
- Lancet. 1974 Jan 12;1(7846):57-8 - PubMed
- Am J Psychiatry. 1956 Jan;112(7):502-9 - PubMed
- J Hist Neurosci. 1992 Apr;1(2):111-8 - PubMed
- Contemp Rev. 1975;226(1309):70-5 - PubMed
- Neurosurgery. 1980 Dec;7(6):598-603 - PubMed
- Neurosurgery. 1984 Sep;15(3):427-44 - PubMed
- Psychiatr Clin North Am. 1994 Sep;17(3):531-40 - PubMed
- Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):205-8 - PubMed
- Br J Pharmacol Chemother. 1953 Jun;8(2):230-6 - PubMed
- Psychopharmacology (Berl). 1986;89(2):138-44 - PubMed
- Cochrane Database Syst Rev. 2000;(2):CD000033 - PubMed
- J Psychoactive Drugs. 1983 Jan-Jun;15(1-2):9-13 - PubMed
- Neuropsychopharmacology. 1991 Sep;5(2):71-84 - PubMed
- Br Med J. 1900 Jan 20;1(2038):134-6 - PubMed
- J Neurosurg. 1979 Jan;50(1):26-30 - PubMed
- Br Med J. 1979 Aug 18;2(6187):429-30 - PubMed
- Anaesthesist. 1952 Dec;1(5):149-50 - PubMed
- J Clin Invest. 1941 Jan;20(1):63-80 - PubMed
Publication Types